[Clinical use of erythropoietin].
The introduction of recombinant human erythropoietin (RHuEPO) has dramatically changed the therapeutic approach to the anemia of chronic renal failure. Clinical studies have also demonstrated that RHuEPO is effectiveness in various non-uremic conditions, such as anemia associated with onco-hematological disorders, prematurity, HIV infection and to reduce the exposure to allogeneic blood in surgical patients. In this review, we briefly analyze the main clinical applications of RHuEPO, with particular attention to the potential complications deriving from its use.
Franchini
Massimo
M
Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona. massimo.franchini@mail.azosp.vr.it
Gandini
Giorgio
G
Lippi
Giuseppe
G
De Gironcoli
Marzia
M
Cantini
Maurizio
M
Aprili
Giuseppe
G
D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D000751:Anemia, Neonatal / Q000188:drug therapy; D001804:Blood Transfusion, Autologous; D002648:Child; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin